ClinicalTrials.gg
CompletedNCT00294164Updated Mar 26, 2014

Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)

A Phase 2/3 interventional study of Serostim® and Placebo in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) and Human Immunodeficiency Virus Infections, sponsored by EMD Serono. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-03-26.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study is a Phase 2/3, multicenter, double-blind, randomized, parallel-group, placebo-controlled, dose-finding trial of Serostim® (mammalian cell-derived recombinant human growth hormone, r-hGH) versus placebo in subjects with human immunodeficiency virus-associated adipose tissue redistribution syndrome (HARS).

The primary study objective is to determine whether Serostim® treatment reduces adipose tissue maldistribution more effectively than placebo. The primary co-endpoints are derived from measures of visceral adipose tissue assessed by computerized tomography (CT) and the ratio of trunk; and limb fat assessed by dual-energy X-Ray absorptiometry (DXA) scans. Anthropometric measures, physical exams, quality of life assessments, serial photographs, and various laboratory measures will be used to address secondary objectives. These secondary objectives relate to the impact of Serostim® on Physician and subject assessments of change in body shape, health-related quality of life, attitude towards medication compliance, metabolic markers, fat redistribution, and safety.

On Day 1, eligible subjects will be randomized in a 1:1:1 ratio to receive daily Serostim®, Serostim® and placebo given on alternate days, or daily placebo. Serostim® doses will be based on body weight, with a maximum dose of 4 milligram (mg).

Therapy will continue for 12 weeks. Treatment will then be altered and the new treatment will be continued through Week 24. Interim Study Visits will be required at Weeks 2 and 4 (Treatment Period 1) and at Weeks 14 and 16 (Treatment Period 2). Subjects will be offered to be enrolled into a maintenance Protocol (Study 23056) at Week 24.

02

Conditions studied

  • Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
  • Human Immunodeficiency Virus Infections

Keywords

  • Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
  • Human Immunodeficiency Virus Infections
  • recombinant human growth hormone (r-hGH)
  • Serostim®
  • Placebo
03

In context

Lead sponsor

EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.

First submitted before EMD Serono became part of Merck KGaA, Darmstadt, Germany.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have an (HIV) infection documented either by viral load as measured by polymerase chain reaction (PCR) amplification; or by the presence of HIV antibodies with confirmation by one of the following:
  • Western blot
  • Immunofluorescence assay
  • Branched Deoxyribonucleic Acid (bDNA) signal amplification
  • The presence of p24 antigen

These tests may have been performed at any time in the past, but the results must be available for review by the Serono monitor prior to randomization

  • Have evidence of excess abdominal adipose deposition when measured using the following cut points:

    • Men: Waist circumference greater than 88.2 centimeter (cm) and waist/hip ratio greater than or equal to 0.95
    • Women: Waist circumference greater than 75.3 cm and waist/hip ratio greater than or equal to 0.9 (23)
  • Be taking antiretroviral medication(s) which is (are) approved or is (are) available under a treatment new drug (IND). The regimen must have remained stable for the 30 days prior to study entry. Subjects must also have agreed not to discontinue or to change their regimen for the duration of the study except as judged medically necessary
  • Have parameter values less than the following limits:

    • (AST), Alanine Aminotransferase (ALT), and amylase less than or equal to 3 times the (Screening)
    • Fasting triglycerides less than or equal to 1,000 milligram per deciliter (mg/dL) (Screening)
    • Fasting glucose less than 110 mg/dL (Screening)
    • Two hour (120 minute) glucose less than 140 mg/dL (following an oral glucose load at Screening)
  • Weigh greater than or equal to 36 kilogram (kg) (79.3 pound)
  • Be between 18 and 60 years of age unless local law dictates different limits
  • Be able and willing to comply with the protocol for the duration of the study
  • Have given written
  • If female, be or surgically sterilized (that is, have undergone tubal ligation or hysterectomy), or is

    • Using a method such as a hormonal contraceptive, intra uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study
    • Not pregnant or breast feeding

Exclusion criteria

Exclusion Criteria:

  • Have an active acquired immune deficiency syndrome (AIDS)-defining Opportunistic Infection (OI) as defined by the Center for Disease Control; or have had an untreated or suspected serious systemic infection, or persistent fever greater than or equal to 101 degree Fahrenheit (°F) (38.3 degree Celsius) during the 30 days prior to study entry
  • Have any active , except for localized cutaneous Karposi's sarcoma (fewer than 10 lesions, none of which are larger than 2 cm, and not on active therapy)
  • Have a central nervous system (CNS) mass or active CNS process associated with neurological findings
  • Have unstable or untreated hypertension, defined as greater than or equal to 140/90 millimeter of mercury (mmHg) at the time of the Screening Visit, and/or has initiated or changed antihypertensive therapy in the 30 days prior to Day 1
  • Have an acute critical illness treated in an intensive care unit, for example, due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure
  • Have any condition, which interferes with or protocol compliance including, but not limited to, active substance abuse and/or dementia
  • Is unable to comply with the concomitant therapy restrictions
  • Have ever been diagnosed with any of the following conditions:

    • Pancreatitis
    • Carpal tunnel syndrome (unless resolved by surgical release)
    • Diabetes mellitus
    • Angina pectoris
    • Coronary artery disease
    • Any disorder associated with moderate to severe edema (for example, cirrhosis, nephrotic syndrome, congestive heart failure, lymphedema)
  • Allergy or to growth hormone
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Serostim® 4 mg daily

    Drug: Serostim®

  • Experimental
    Serostim® 4 mg alternate days

    Drug: Serostim® · Drug: Placebo

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugHuman Growth HormoneStudies of Human Growth HormoneHuman Growth Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.

    Also known as: Recombinant human growth hormone (r-hGH)

  • DrugPlacebo

    Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in absolute area of visceral adipose tissue quantified by Computerized Tomography (CT) scan at Week 12

    Time frame: Baseline and Week 12

  2. Change from Baseline in the ratio of trunk fat to limb fat quantified by Dual-Energy X-Ray Absorptiometry (DXA) scan at Week 12

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change from Baseline in composite sum of the visceral adipose tissue and the ratio of trunk fat to limb fat at Week 12

    Time frame: Baseline and Week 12

  2. Dorsal fat area in the transverse plane, as measured by Computerized Tomography (CT) Scan

    Time frame: Baseline, Week 12 and 24

  3. Weight measured on a calibrated scale

    Time frame: Baseline, Week 12 and 24

  4. Absolute values of maximal chest, waist, and hip circumference

    Time frame: Baseline, Week 12 and 24

  5. Waist/hip ratio

    Time frame: Baseline, Week 12 and 24

  6. Absolute value of dorsocervical fat

    Time frame: Baseline, Week 12 and 24

  7. Absolute value of total body fat as quantified by DXA scan

    Time frame: Baseline, Week 12 and 24

  8. Absolute value of trunk and Limb fat quantified by DXA scan

    Time frame: Baseline, Week 12 and 24

  9. Absolute value of Lean body mass as quantified by DXA scan

    Time frame: Baseline, Week 12 and 24

  10. Absolute concentration of serum insulin and glucose

    Time frame: Baseline, Week 12 and 24

  11. Absolute concentration of fasting serum triglyceride, total cholesterol, Low density lipoprotein (LDL), High density lipoprotein (HDL) and very low density lipoprotein (VLDL)

    Time frame: Baseline, Week 12 and 24

  12. High density lipoprotein (HDL)/Low density lipoprotein (LDL) ratio

    Time frame: Baseline, Week 12 and 24

  13. Change from Baseline in Serial Photography Parameters of chest and abdomen at Week 12 and 24

    Time frame: Baseline, Week 12 and 24

  14. Health related Quality of life

    Time frame: Baseline, Week 4, 12 and 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, Saag M, Bock D, Simons G, Gertner JM; Serostim in Adipose Redistribution Syndrome Study Group. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):239-52. doi: 10.1097/00126334-200403010-00004. Erratum In: J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):381. PubMed 15076238 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2001, a primary completion of May 2002 and a completion of May 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2006
First posted
Feb 20, 2006
Start
Mar 2001
Primary completionActual
May 2002
CompletionActual
May 2002
Last update
Mar 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00294164
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Feb 20, 2006
Start date
Mar 2001
Primary completion
May 2002
Completion
May 2002
Last update
Mar 26, 2014

Study contacts

Ellen Brady, M.D. MPH
study director · EMD Serono
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion